Defining the role of TORC1/2 in multiple myeloma

Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia

(2010) A. M. Roccaro et al.   BLOOD

Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production

(2010) S. Zhang et al.   BLOOD

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

(2010) B. Hoang et al.   BLOOD

A Ras Signaling Complex Controls the RasC-TORC2 Pathway and Directed Cell Migration

(2010) Pascale G. Charest et al.   DEVELOPMENTAL CELL

NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells

(2010) Sally K Martin et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Ras-mediated activation of the TORC2–PKB pathway is critical for chemotaxis

(2010) Huaqing Cai et al.   JOURNAL OF CELL BIOLOGY

DEPTORexpression and response to thalidomide: toward a new therapeutic target in multiple myeloma?

(2010) Javier de la Rubia et al.   LEUKEMIA & LYMPHOMA

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

Dissecting the role of mTOR: Lessons from mTOR inhibitors

(2009) Ryan J.O. Dowling et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy

(2009) Ryan J.O. Dowling et al.   BIODRUGS

Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia

(2009) A. M. Roccaro et al.   BLOOD

RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma

(2009) A. K. Azab et al.   BLOOD

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

(2009) A. K. Azab et al.   BLOOD

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens

(2009) Alice C Fan et al.   NATURE MEDICINE

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia

(2008) A. M. Roccaro et al.   BLOOD

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA